07:37 AM EST, 11/03/2025 (MT Newswires) -- Axsome Therapeutics ( AXSM ) reported a Q3 net loss Monday of $0.94 per diluted share, narrowing from a loss of $1.34 a year earlier.

Analysts surveyed by FactSet expected a loss of $0.82.

Total revenue for the quarter ended Sept. 30 was $171 million, compared with $104.8 million a year earlier.

Analysts surveyed by FactSet expected $163 million.

Axsome said it expects its $325.3 million in cash and cash equivalents as of Sept. 30 to be sufficient to fund operations into cash flow positivity.

Shares of Axsome Therapeutics ( AXSM ) were down 1.2% in recent premarket activity Monday.